COVID-19 continues to affect leading causes of death in US: CDC
By
Kimberly Bonvissuto
Aug 12, 2024
The COVID-19 pandemic radically altered the rankings of the leading causes of death in the United States in 2020, and although COVID ranks lower on the list of causes in 2023, its effects continue to be...
15 million COVID-19 vaccine doses wasted in U.S. since March 1
Sep 02, 2021
Reasons why doses may be marked as wasted include a cracked vial, an error diluting the vaccine or a freezer malfunction.
Prolonged SARS-CoV-2 risk varies across immunosuppressive conditions
Jan 31, 2024
Severely immunocompromised individuals had greater SARS-CoV-2 evolution and a higher risk for developing resistance against therapeutic mAbs.
CDC calls emergency meeting on heart inflammation link to COVID-19 vaccines
Jun 11, 2021
The agency has identified 226 reports so far that may meet its ‘working case definition’ of myocarditis and pericarditis.
Postexposure prophylaxis with nirmatrelvir-ritonavir does not cut COVID-19 Infection
Jul 18, 2024
No significant reduction was seen in the risk for symptomatic SARS-CoV-2 infection with postexposure prophylaxis for five or 10 days.
Hospital-onset SARS-CoV-2 infection during omicron linked to morbidity
Jul 15, 2024
Hospital-onset SARS-CoV-2 remained associated with increased morbidity and mortality during the omicron era.
Subcutaneous mAb may benefit high-risk outpatients with COVID-19
Apr 12, 2022
SC casirivimab and imdevimab were linked to reduced 28-day hospitalization or death for high-risk outpatients with mild to moderate COVID-19.
Guillain-Barré syndrome may be triggered by SARS-CoV-2 infection
Sep 24, 2021
“Our study shows that COVID-19 may precede Guillain-Barré syndrome in rare cases,” a coauthor said in a statement, “but the existence of a true association or causal relation still needs...
More coronavirus relief may come before end of year, senator says
By
Lois A. Bowers
Nov 20, 2020
Congress may pass another coronavirus relief bill before the end of the year, Sen. Mark Warner (D-VA) said Thursday at the American Seniors Housing Association’s Chairman’s Circle virtual event.
SARS-CoV-2 mAbs continued to be used after FDA deauthorization
Aug 30, 2022
More than 158,000 doses of bamlanivimab-etesevimab and casirivimab-imdevimab were used after deauthorization on Jan. 24, 2022.